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Abstract
The process of autophagy is integral to cellular function. In this process, proteins, organelles, and metabolites are
engulfed in a lipid vesicle and trafficked to a lysosome for degradation. Its central role in protein and organelle
homeostasis has piqued interest for autophagy dysfunction as a driver of pathology for a number of diseases
including cancer, muscular disorders, neurological disorders, and non-alcoholic fatty liver disease. For much of its
history, the study of autophagy has centered around proteins, however, due to advances in mass spectrometry and
refined methodologies, the role of lipids in this essential cellular process has become more apparent. This review
discusses the diverse endogenous lipid compounds shown to mediate autophagy. Downstream lipid signaling
pathways are also reviewed in the context of autophagy regulation. Specific focus is placed upon the Mammalian
Target of Rapamycin (mTOR) and Peroxisome Proliferator-Activated Receptor (PPAR) signaling pathways as
integration hubs for lipid regulation of autophagy.
Keywords: Autophagy, Lipids, Mammalian target of rapamycin, Peroxisome proliferator-activated receptor, Fatty
acids, Phospholipids, Sphingolipids
Introduction
Autophagy is a process by which proteins, organelles, and
metabolites are broken down and turned over often as a
response to starvation or as a means to protect the
cell from damage. Autophagy pathways come in three
forms, macroautophagy, microautophagy, and chaperone-
mediated autophagy [1]. Of these, macroautophagy is the
best characterized and most well understood. Macroauto-
phagy (hereafter referred to as autophagy) was originally
studied in yeast and involves the formation of lipid vesicles
known as autophagosomes that engulf cargo to be de-
graded. Once formed, the autophagosome is trafficked to a
lysosome and a fusion event occurs resulting in the degrad-
ation of the cargo within the autophagosome (Fig. 1) [1].
Autophagy is delineated into key events: initiation, nu-
cleation, elongation and formation of a mature
autophagosome, fusion of the autophagosome with a
lysosome, and degradation of cargo. The initiation of au-
tophagy is tightly regulated by the mTOR complex 1 [2].
When the cell is in a nutrient-rich state, mTORC1 is ac-
tive and autophagy is suppressed, however, during
nutrient-poor conditions, mTOR is inhibited which al-
lows for the formation of Unc-51 like kinase (ULK) initi-
ation complex composed of ULK kinases, autophagy-
related protein 13 (Atg13), Autophagy related protein
101 (Atg101), and RB1-inducible coiled-coil protein 1
(FIP200) [3]. Furthermore, ULK-1 also activates a second
complex composed of Beclin1-vacuolar protein sorting
protein 34 (VPS34)-autophagy related protein 14
(Atg14L)-P150, which produces phosphatidylinositol-3-
phosphate (PI3P) (Fig. 1) [4]. This complex is respon-
sible for autophagic vesicles budding from the endoplas-
mic reticulum and forming a structure known as an
omegasome. In mammals, this is the site responsible for
the nucleation of autophagosomes [5]. Next, phosphati-
dylethanolamine (PE) is conjugated to microtubule-
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associated light protein light chain 3 (LC3) by autophagy-
related protein 7 (Atg7) and autophagy-related protein 3
(Atg3), which are ubiquitin-like conjugating enzymes.
Then the conjugated PE-LC3 is inserted into the autopha-
gosome membrane [6]. In addition, autophagy-related
protein 12 (Atg12) is conjugated to autophagy-related pro-
tein 5 (Atg5) by Atg7 and autophagy-related protein 10
(Atg10) also in a ubiquitin-like manner [7]. Atg12-Atg5
interacts with autophagy-related 16 like protein (Atg16L)
and promotes elongation [8]. Meanwhile, cargo is selected
by ubiquitination and interaction with cargo receptor pro-
teins p62/ Sequestome 1 (sqstm1). Cargo bound to p62
then binds to the p62 interacting regions of LC3 [9]. After
the cargo is selected, the autophagosome matures by dis-
assembling the autophagy-related proteins from the outer
layer with the help of myotubularin 3 (MTMR3), a PI3P
phosphatase [10]. Once matured, the autophagosome will
fuse with early and late endosomes as well as with lyso-
somes this is mediated by Rubicon, UV resistance-
associated gene (UVRAG), Ras-related protein 7 (Rab7),
snap receptor proteins (SNAREs), and Lysosome-
associated membrane glycoproteins (LAMPs) [11–13].
Once fusion with a lysosome is complete, the cargo is de-
graded. In mammals, lysosomal hydrolases break down
cargo. Beneficial components, such as amino acids are
then returned to the cytosol via amino acid efflux proteins
such as vacuolar amino acid transporter 3 (Avt3) and
vacuolar amino acid transporter 4 (Avt4) [14].
Lipid signaling directs autophagy
While autophagy has been studied extensively over the
years, the role of lipids in this process is underrepre-
sented. Historically, working with lipids has presented a
challenge, leading to an emphasis on work that primarily
focused upon protein contributions. However, recent
advances in both mass spectrometry capabilities and
methodologies have spurred considerable progress in the
study of lipids. For example, lipophagy, the targeted
breakdown of lipid droplets by autophagic pathways, is
currently being studied in the context of non-alcoholic
fatty liver disease, aging, and cancer. It is becoming more
apparent that lipids play a prominent role in autophagy.
mTOR, the master regulator of cell growth, metabolism,
and autophagy is itself a part of a signaling cascade in
which lipid phosphoinositides are involved. In addition,
Peroxisome Proliferator-activating factors (PPARs), are
nuclear receptors that respond to lipid signals and have
been implicated in the control of autophagy and
autophagy-related genes. For all of these reasons, this re-
view seeks to provide a comprehensive overview of the
Fig. 1 Autophagy mechanism. Autophagy is a cellular mechanism by which metabolites, organelles, proteins, and protein aggregates are
enveloped by a vesicular membrane to form an autophagosome. The autophagosome is trafficked to a lysosome where fusion occurs, and
lysosomal degradative enzymes break down the cargo
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growing field of lipid signaling. In the subsequent sec-
tions of this article, we discuss the different lipid signal-
ing pathways known to regulate autophagy and their
implications in disease states.
Impaired autophagy in human disease
Autophagy is of considerable interest as a potential target for
treatment in many diseases that include cancer, muscular
disorders, and neurodegenerative disease. The fundamental
role for organelle, particularly mitochondria, and biomol-
ecule turnover by autophagy provides a broad influence of
this process in cellular physiology. In addition, autophagy is
the only known cellular process for removing protein aggre-
gates making the study of this process of considerable inter-
est in protein aggregation disorders which coincide with
numerous neurodegenerative diseases. Therefore, under-
standing and developing tools to manipulate autophagy
could yield widespread therapeutic benefits.
Due to its regulation by mammalian target of rapamy-
cin (mTOR), autophagy is intimately involved in growth,
cell death, and cytoprotective processes. As a result,
there is great interest in harnessing this process in the
context of cancer. In the early stages, suppression of au-
tophagy is believed to facilitate the uncontrolled growth
[15]. In later stages, cells may require increased autoph-
agy in low-oxygen and low-nutrient conditions, such as
those seen in tumors [16]. Autophagy also can protect
tumors from ionizing radiation by helping to remove
damaged organelles and proteins [17]. Dysfunction in
the phosphatidylinositol-3-kinase (PI3K)-protein kinase
B (Akt)-mTOR pathway has been commonly seen to re-
sult in altered autophagy. This pathway, when active,
suppresses autophagy and uses lipid signaling molecules
such as phosphatidylinositol-3,4,5-triphosphate (PIP3) as
key signal transducers [18]. Mutations in phosphatase
and tensin homolog (PTEN), a phosphatase that antago-
nizes PI3K and causes positive regulation of autophagy,
result in aberrant inhibition of autophagy that has been
associated with excessive growth and tumor formation
[19]. Another common mutation in cancers that leads to
autophagy dysfunction is Beclin-1. A high percentage of
human breast, ovarian, and prostate cancers have a het-
erozygous mutation in this gene. Beclin-1 is a part of the
initiation complex responsible for activating lipid kinases
required for the formation of autophagosomes. In breast
carcinoma cell line MCF7, it has been established that
Beclin-1 expression is below detectable limits, and trans-
fection of the Beclin-1 gene upregulates autophagy [15].
Studies have also shown that mice with a heterozygous
deletion of Beclin-1 are more susceptible to developing
tumors [20, 21]. This is further evidence of the role of
beclin-1 and autophagy play in cancer.
Autophagy has also been implicated in muscular disor-
ders. It is common for autophagy to play an important
role in post-mitotic cells, such as muscle cells and neu-
rons due to the potential for damage from the accumu-
lation of dysfunctional or toxic molecules, protein, or
organelles. Vacuolar myopathy is a type of muscular dis-
ease in which the structure of lysosomes is abnormal ei-
ther from a deficiency in lysosomal enzymes or a
deficiency in lysosomal membrane proteins [22]. There-
fore, it is not surprising that diseases in which lysosomal
function is affected also result in altered autophagy. In
fact, an accumulation autophagosomes is typically re-
quired to diagnose vacuolar myopathies [23]. In addition,
an autophagy-related gene has been associated with a
vacuolar myopathy known as Danon’s disease. In Danon’s
disease, mutations in lysosome-associated membrane pro-
tein 2 (LAMP-2) have been identified [23]. LAMP-2 is a
lysosomal membrane protein whose function is still not
fully understood. However, studies in which the Lamp2
gene is deleted in mice result in a Danon’s disease-like
phenotype and accumulation of autophagosomes [23].
Autophagy has long been thought to play an important
role in neurodegenerative disorders. A prominent hall-
mark of these diseases is the accumulation of protein ag-
gregates associated with neuronal loss in the brain.
Noted examples include ɑ-Synuclein Lewy bodies in Par-
kinson’s disease, Tau neurofibrillary tangles in Alzhei-
mer’s disease, Superoxide dismutase 1 (SOD1)-mediated
aggregates in Amyotrophic Lateral Sclerosis, and mutant
Huntingtin protein aggregates in Huntington’s disease
[24–28]. It is speculated that these aggregates may be
substrates for autophagy. It is also thought that in these
disease states, autophagy is disrupted. Several proteins
have been identified and are linked to dysfunction in
various steps of autophagy in each of these diseases. For
example, in Alzheimer’s disease, autophagy induction is
disrupted by reduced expression of Beclin-1 [29]. In Par-
kinson’s disease, an overexpression of ɑ-Synuclein causes
the inhibition of GTPase Rab1. This inhibition is respon-
sible for the mislocalization of autophagy-related protein
9 (Atg9), a protein involved in the formation of autopha-
gosomes [30]. Also, PTEN induced kinase 1(PINK1) and
Parkin are proteins involved in the recognition of dam-
aged mitochondria normally targeted for degradation
mitophagy. Loss of function mutations in these proteins
can prevent the necessary destruction of damaged mito-
chondria through autophagy resulting in cell death [31,
32]. In addition, the park9 gene encodes lysosomal type
5 P-type ATPase (ATP13A2). Autosomal recessive mu-
tations in the park9 gene result in levodopa-responsive
early-onset Parkinson’s Disease. This loss of function
mutation is responsible for aberrant expression of zinc
transporters and impairment in the ability for Zn 2+ to
enter lysosomal vesicles resulting in an induction of
reactive oxygen species and impairment of mitochon-
drial function [33]. In Huntington’s disease, mutant
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huntingtin protein is known to affect several stages in
autophagy [32]. Many research groups have reported
changes in the expression of mRNA corresponding to
genes in the autophagic pathway [34]. In addition, a
polymorphism in the ATG7 gene has been linked to
early-onset Huntington’s Disease [35].
Phospholipids, sphingolipids, and mTOR signaling
Phosphoinositides are a class of phospholipids derived
from phosphatidylinositol, which is found in the inner
layer of the cell membrane and are commonly used by
the cell as signaling molecules [36]. They play a major
role in the regulation of autophagy through phosphoryl-
ation and dephosphorylation at the 3,4 and 5-hydroxyl
positions of the inositol ring. They control the pathway
that directly activates or deactivates mTOR [37]. mTOR
itself is a master regulator of growth, anabolic processes,
and autophagy. Generally, mTOR is activated in re-
sponse to insulin, other nutrients such as amino acids or
triglycerides, and growth factors. When active, mTOR
promotes growth and suppresses autophagy. In response
to starvation, the cell inhibits mTOR, and autophagy is
promoted [2].
The canonical signaling pathway that controls autoph-
agy through PIP3. The pathway begins as a response to
insulin, other nutrients, or growth factors [38]. Phos-
phoinositide 3-kinases convert phosphatidylinositol 4,5-
bisphosphate (PIP2) to PIP3. PIP3 activates
phosphoinositide-dependent kinase-1 (PDK1) which in
turn phosphorylates Akt [39, 40]. Akt then phosphory-
lates tuberous sclerosis 2 (TSC2) which results in the in-
hibition of tuberous sclerosis 1/2 (TSC1/2) complex
[41]. When inhibited, TSC1/2 cannot activate Rheb
GTPase activity permitting activation of mTOR. When
bound to GTP, Rheb mediates the activation of mTOR
complex 1 (mTORC1) which, in turn, inhibits autophagy
[42]. Activated mTORC1 inhibits autophagy by inhibit-
ing the ULK1 initiation complex. Pro-autophagy signals
result in ULK1 dissociation from mTOR and autophagy
initiation is facilitated (Fig. 2) [43].
PI3P also plays an integral role in the process of au-
tophagy by interacting with VPS34 [44]. Originally iden-
tified and studied in yeast, VPS34 is a class III
phosphatidylinositol 3 kinase. In yeast, VPS34 forms one
of two complexes. VPS34 complex-I is composed of
VPS34, VPS30/ATG6, VPS15, and ATG14 and is impli-
cated in the initiation of the pre-autophagosomal struc-
ture (PAS) [45, 46]. In Mammals, VPS34 is thought to
play a similar role in autophagy initiation. However, it
has been difficult to study in mouse models since pan
knockouts of VPS34 are embryonically lethal, and there
are no inhibitors specific to VPS34 necessitating the use
of low specificity inhibitors, such as wortmannin or 3-
MA [47]. Conditional knockout studies using cultured
mice embryonic fibroblasts have shown that VPS34 is
required for the formation of autophagosomes [48]. In
addition, VPS34 is involved with mTOR regulation of
autophagy. Studies using mice embryonic fibroblasts
have shown that mTORC1 must be inactivated for the
VPS34 initiation complex to be active and that mTORC1
can inhibit the phosphatidylinositol 3-kinase activity of
this complex by phosphorylating ATG14 [48]. PI3P is
also a component of the autophagosome. It has been ob-
served to be enriched in the concave surface of early
Fig. 2 PI3K-mTOR autophagy pathway utilizes PIP3 lipid signaling. PI3K converts the lipid PIP2 to PIP3. PIP3 mediates the phosphorylation of
PDK1 causing the activation of AKT. AKT inhibits the activation of the TSC1/2 complex by phosphorylating TSC2. The inhibition of the TSC1/2
complex results in inhibition of Rheb GTPase which in turn activates mTORC1. MTORC1 inhibits the activation of the ULK activation complex
leading to an inhibition of autophagy. Inversely, phosphatase activity of PTEN converts PIP3 to PIP2 which suppresses the activation of PDK1 and
downstream AKT. Inhibited AKT cannot suppress the TSC1/2 complex allowing Rheb GTPase to remain active. An active Rheb results in inhibition
of mTORC1 and an activation of the ULK1 complex
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phagophores [49]. Because of this, PI3P is thought to fa-
cilitate the expansion and sealing of autophagosomes.
In addition to its function in the autophagosomal mem-
brane, PI3P is thought to mediate selected cargo capture
via its interaction with autophagy linked FYVE protein
(Alfy), a nuclear scaffold protein with a FYVE domain that
binds PI3P [50]. In the autophagic process, Alfy interacts
with Ath5 and P62 through its WD40 domain and with
PI3P through its FYVE domain. The high amount of PI3P
in the inner membrane of autophagosomes is believed to
act as a dock for this Alfy/Atg5/P62 complex in the select-
ive engulfment of protein aggregates that results in aggre-
gate clearance known as aggrephagy [51].
Metabolites formed from the breakdown of phospho-
lipids are also involved in autophagy. Phosphatidic acid
is formed by the breakdown of phosphatidylcholine into
choline and phosphatidic acid by Phospholipase D [52].
Phosphatidic acid plays a role in autophagy by inducing
membrane curvature due to its cone shape. In addition,
Phosphatidic acid is formed as a result of an absence of
nutrients and serves as an inhibitor of mTORC1 thus
acting as a positive regulator of autophagy [53]. Phos-
phatidic acid can also be converted into diacylglycerol
by the Phosphatidic Acid Phosphatases which has other
autophagy regulating properties [54]. Diacylglycerol
modulates autophagy by activating Protein Kinase C
which induces autophagy by disrupting the B-cell
lymphoma protein 2 (Bcl-2)-Beclin-1 complex via c-Jun
N terminal kinase (JNK) and Nicotinamide adenine di-
nucleotide phosphate (NADPH) oxidase [54].
Sphingolipids are a class of lipids involved in several
processes ranging from apoptosis to cell proliferation to
differentiation, inflammation, and autophagy [55]. In au-
tophagy, two sphingolipids have been found to play
sizeable roles, ceramide and sphingosine − 1-phosphate.
Ceramide activates autophagy by inhibiting Akt and
resulting in an inactivation of mTOR and an upregulation
of Beclin-1 function [56]. Sphingosine-1-phosphate is
formed by the hydrolysis of ceramide into sphingosine
followed by its phosphorylation by Sphingosine Kinases 1
and 2 [57]. Sphingosine Kinase 1 is activated by starvation
signals and drives the formation of sphingosine-1-
phosphate [57]. In addition, sphingosine kinase 1 inhibits
mTORC1 independently of Akt while upregulating beclin-
1 expression, ultimately promoting cell survival [57].
Signaling through the PPAR family
PPARs are a family of nuclear receptor proteins that act
as transcription factors. There are 3 isoforms of PPARs
in mammals, PPARα, PPARδ, and PPARγ [58]. All 3 iso-
forms of PPARs must bind with a Retinoid Receptor X
(RXR) and a lipid ligand in order to act as transcription
factors (Fig. 3) [59]. Generally, they have been reported
to bind to oleic acid, linoleic acids, linolenic acids,
prostaglandins, eicosanoids, and oxidized lipids with the
help of fatty acid-binding proteins which bind lipophilic
ligands in the cytoplasm and shuttle them to their target
PPAR [60, 61]. PPARs bind to their ligands through the
ligand-binding domain (LBD). These domains consist of
12 α-helices arranged into an ‘antiparallel helix sand-
wich’ and a three-stranded antiparallel β-sheet. The
ligand-binding site is located in the core of the ligand-
binding domain that is formed by helices 3,5,7,11, and
12. The cavity formed by these helices is T-shaped [62].
In order for ligands to bind to PPAR-α or PPAR-γ, they
must be able to form a U-shaped conformation, and to
bind to PPAR-delta ligands must form an L-shaped con-
formation [63]. All PPARs isoforms have been shown to
modulate autophagy in the context of different diseases
and cellular responses.
PPARα is primarily expressed in the liver, brown adi-
pose tissue, heart, and kidney. It promotes uptake and
catabolism of fatty acids by helping to express fatty acid
transport and binding genes [58, 64]. It has been thought
to be involved in the innate immune response during
mycobacterium infection [65]. In studies with tubercu-
losis infected bone-derived macrophages, PPARα was
shown to stimulate autophagy and autophagosomal mat-
uration, while suppressing inflammatory responses. It
was determined that following PPARα activation, Tran-
scription Factor EB (TFEB) was activated and a series of
autophagy and lysosomal genes were expressed such as
LAMP3 and Rab7 [65]. Based on this work, it is thought
that, in mycobacterial infections, such as tuberculosis,
PPARα is activated and in turn activates TFEB. Together
they promote the expression of autophagy-related genes
that stimulate autophagy (Fig. 3).
PPAR δ has high expression levels in the colon, small
intestine, liver, heart, lung, and brain. It plays an import-
ant role in diseases such as diabetes, obesity, atheroscler-
osis, and cancer [58, 64]. This is especially poignant
because there are great efforts in exploiting autophagy as
possible treatments for cancer and diabetes. Studies in
mice cells have shown a marked decrease in autophagic
markers associated with the knockout of PPAR δ sug-
gesting its involvement in autophagy [66].
Finally, PPARγ is expressed in adipose tissue, the in-
testines, and macrophages. It is usually involved in fatty
acid storage, glucose uptake, and adipogenesis [58, 64].
Because of its role in controlling the availability of nutri-
ents, there has been an interest in targeting it as a treat-
ment for cancer. In Colorectal cancer, studies with
Caco-2, a common colorectal cancer cell line, have
shown that activation of autophagy occurs following
treatment with PPARγ agonist rosiglitazone [67]. In
addition, inhibition of autophagy with 3-MA was ob-
served to induce the expression of PPARγ. PPARγ was
determined to cause the induction of PTEN, an
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antagonist to PI3K which dephosphorylates and reduces
the concentration of PIP3 [67]. This results in the overall
inhibition of the mTOR pathway and induces autophagy.
In the context of breast cancer, PPARγ has also been im-
plicated to modulate autophagy. Activation of PPARγ by
agonist troglitazone was shown to induce autophagy in
MDA-MB231 cells as determined by the measurement
of acidic vesicular organelles by staining with Acridine
orange [68]. In addition, studies of constitutively active
PPARγ suggest that it is sufficient for the activation of
autophagy leading to the belief that autophagy acts to
protect cancer cells (Fig. 4) [68].
Lipid metabolism and autophagy
Autophagy is intricately related to the metabolism of
lipids, namely triglycerides because it responds to the
presence or absence of nutrients in the cell. Further-
more, it is involved with the breakdown of stored lipids
in the cell. Triglycerides are stored in organelles known
as lipid droplets. They are used to generate energy,
Fig. 4 PPARγ mediated activation of autophagy. PPARγ promotes the expression of PTEN. High amounts of PTEN lead to lower concentrations of
PI(3,4,5)P3. Less PI(3,4,5)P3 inhibits the activation of PDK1 and ultimately results in inhibition of mTORC1 which causes an activation of autophagy
Fig. 3 Overview of PPAR signaling and mechanism for PPARα-mediated autophagy activation in innate immune system. Initially, lipid molecule
enters the cell and is quickly bound by a fatty acid binding protein. The fatty acid binding protein transports the lipid to a PPAR which in turn
activates a corresponding RXR. The PPAR-RXR complex crosses into the nucleus and facilitate expression of required genes. In the case of
tuberculosis infection, PPARα upregulates the expression of TFEB which, in turn, drives the expression of autophagy related genes, LAMP3 and
RAB7 thus stimulating autophagy
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building blocks for membranes, and for lipid signaling
[69]. Lipid droplets are broken down for use by the cell
via lipophagy. This process is mediated by the GTPase
Rab7 in hepatocytes and results in the release of free
fatty acids under starvation conditions to be used as fuel
in the mitochondria and undergo β-oxidation. Rab7 was
shown to mediate the docking of autophagosome to lipid
droplets facilitating their catabolism [70]. In addition,
Adipose triglyceride lipase (ATGL) is a regulator of lipo-
phagy. When knocked down in hepatocytes, ATGL
causes decreased lipophagy. This ATGL signaling has
been observed to occur through sirtuin 1. Together,
these two proteins drive lipophagy and fatty acid oxida-
tion [71].
Additionally, the breakdown of lipid droplets by lipo-
phagy can be regulated by transcription factors. TFEB me-
diates the activation of PPAR alpha as a response to
nutrient deprivation in order to activate lipophagy [72]
Additionally, forkhead homeobox protein O1 (FOXO1)
becomes upregulated in nutrient restricted conditions and
increases lipophagy of lipid droplets. The FOXO1 medi-
ated lipophagy activation is facilitated by an increased ex-
pression of lysosomal acid lipase (LIPA) resulting in a
release of free fatty acids through adenosine monopho-
sphate kinase (AMPK)-dependent β-oxidation in adipo-
cytes in nutrient restricted conditions [73].
Conversely, autophagy is linked to the biosynthesis of
new triglycerides as well. Not only does autophagy drive
the breakdown of lipid droplets, but it is also tied to the
metabolic balance of liver triglycerides. Diets low in pro-
tein result in reduced expression of autophagy receptor
SQstm1 and increases the expression of LC3-II. This
correlates to the induction of autophagy. It is speculated
that, in the case of low protein availability, autophagy
does not catabolize lipids and instead may help triglycer-
ides to accumulate in the liver [74]. Additionally,
Perilipin-2, a protein that associates with lipid droplets,
has been observed to protect lipid droplets from autoph-
agy. Perilipin-2 has been observed to inhibit lipogenesis
and triglyceride production as well as upregulating au-
tophagy when it is depleted in the cell [75].
Free fatty acids and cholesterol
Free fatty acids have also been implicated in the autoph-
agic pathway. Although they usually act as nutrients,
fatty acids can induce cell death when they accumulate
in excessive levels in non-adipose cells and tissues. This
is known as lipotoxicity and has been observed in dis-
eases such as obesity, diabetes, and non-alcoholic fatty
liver disease [76]. As a result, levels of free fatty acids are
thought to be regulated inside the cell through lipophagy
[69]. Palmitic acid (PA) and its effects on diabetes has
been studied in rat pancreatic beta-cell line INS-1 [77].
It was determined to trigger autophagy independently of
the mTOR pathway. For instance, autophagy was shown to
be promoted by stimulating JNK which leads to phosphoryl-
ation of Bcl-2 a resulting in its dissociation from Beclin-1
which in turn allowed for the initiation of autophagy and
autophagosome formation [77]. In addition, protein kinase C
(PKC) isoforms δ, ɑ, and Θ have also been implicated in PA-
mediated autophagy regulation [78].
Studies suggest that in mice embryonic fibroblasts, PA,
a saturated fatty acid can induce autophagy [79]. It was
reported that palmitic acid was able to increase the
amount of LC3, suggesting the induction of autophagy.
However, there was no increase in phosphorylation of
P70S6K or S6, two downstream proteins in the mTOR
signaling pathway [79]. This suggests that PA induces
autophagy independent of mTOR. PKCɑ was identified
and shown to be involved in the autophagy inducing
process. When it was knocked down with siRNA, LC3
detection fell [79]. Furthermore, studies show that while
prolonged exposure to PA causes cell death, short term
exposure induces autophagy, this suggests that autoph-
agy is an important protective measure against lipotoxi-
city caused by PA [79].
PA has been shown to modulate autophagy via a sec-
ondary signaling pathway. Its effects have been studied in
the context of hepatic steatosis; a condition caused by high
amounts of fat in the liver [80]. In hepatic steatosis, high
lipid levels cause lipotoxicity. Non-alcoholic steatohepati-
tis mice were fed a high-fat diet. These mice were shown
to exhibit high autophagy mediated by PA [80]. In these
studies, autophagy was determined to be regulated by the
activation of mitogen-activated protein kinase (MAPK),
extracellular signal-regulated kinase (ERK), P38, JNK.
Based on these studies, researchers concluded that JNK-1
has a lipo-apoptotic effect while JNK-2 promotes autoph-
agy and has a cytoprotective effect (Fig. 5) [80].
In addition to PA, myristic acid (MA) has been studied
for its autophagy regulating effects. Like palmitic acid,
MA is a saturated fatty acid commonly used by the body
as a nutrient. In the context of autophagy, MA has been
found to promote overexpression of Beclin-1 gene
BCN1 and increased conversion of LC3-I to LC3-II in
mouse cardiomyocytes [81]. MA is thought to work to
upregulate autophagy by producing C14-ceramide and
upregulating ceramide synthase 5 (Fig. 5) [81].
Omega-3 polyunsaturated acids have been known to
play a role in regulating autophagy. The most studied of
these is docosahexaenoic acid (DHA). DHA is a compo-
nent in many of the phospholipids that make up the cell
membrane in the brain, skin, and retinal tissue [82]. It
has been studied in myocardioblasts and various human
cancer cell lines [83–85]. DHA has been implicated in
the p53-AMPK-mTOR signaling pathway. It has been
shown to work through AMPK to inhibit mTOR and in-
duce autophagy in human cancer cells with wild type
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p53 [86]..However, In prostate cancer cells with mutant
p53, DHA was observed to induce autophagy through
the creation of mitochondrial reactive oxygen species
that results in the inactivation of AKT and mTOR also
resulting in the activation of autophagy (Fig. 5) [87].
Finally, autophagy is related to cholesterol biosynthesis
inversely through the mTOR signaling pathway. When
cholesterol biosynthesis is inhibited, there is an induc-
tion of autophagy. Inhibition of cholesterol biosynthesis
by statin drugs such as simvastatin has been linked to
autophagy activation via the inhibition of the mTOR sig-
naling pathway in human blood cancer cells. It was de-
termined that the statin drug caused this activation only
through cholesterol depletion when the cholesterol de-
pleting agent, methyl-β-cyclodextrin also produced acti-
vation of autophagy [88]. Likewise, a deficiency of
transmembrane 7 superfamily member 2 (TM7SF2), a
positive regulator of cholesterol biosynthesis, results in
repression of autophagy. Removal of TMS7F2 causes in-
creases in the expression of fatty acid degradative en-
zymes, decreased lipid accumulation, and in turn,
decreased autophagy in mice exposed to Lipopolysac-
charide [89].
Conclusion and future perspectives
This review aims to outline the current state in the field
of lipid regulation of autophagy. To that end, this review
has discussed a myriad of ways in which many lipids are
involved in the process of autophagy and its regulation.
All the lipids discussed along with their functions and
effects on autophagy have been summarized in Table 1.
Autophagy represents a cellular process that has impli-
cations for several important areas of study. Phospho-
lipids and their derivatives have been shown to not only
be an important part of the regulation of autophagy
through the crucial mTORC1 signaling pathway but also
an integral part of the autophagy machinery. These
lipids have also been shown to affect a variety of pro-
cesses by acting through PPARs with the possible impli-
cation in human disease. Finally, dietary lipids and
cholesterol have been implicated in the regulation of au-
tophagy both through the canonical mTOR pathway and
alternative means.
The role lipid molecules play in autophagy represents
the potential for many new avenues of research. Under-
standing it can give us a better, more holistic idea of this
process which is central to many cellular functions and
disease states. As our understanding of autophagy has
grown, its activators and inhibitors have begun to appear
as a novel area of drug development. As a result, it is ne-
cessary to fill in the gaps in our knowledge concerning
lipid signaling. In the specific case of disease, it may be
necessary to identify novel lipid molecules involved in
autophagy. It may also be helpful to determine if there is
a link between the signaling pathways described or if
they all act independently. Finally, if autophagy is to be
exploited as a potential treatment for disease, it would
be necessary to evaluate the effects these lipid molecules
and signaling pathways have on cellular functions related
to autophagy.
The technology we use to understand autophagy has
increased greatly over the past years, and it has allowed
Fig. 5 Overview of regulation of autophagy by free fatty acids. Palmitic acid stimulates autophagy by activating JNK and has been shown to
interact with PKC isoforms which have been implicated in autophagy regulation. Myristic acid has been shown to upregulate autophagy by
producing C-14 ceramide. DHA has been implicated in the P53-AMPK-mTOR pathway resulting in activation of autophagy
Soto-Avellaneda and Morrison Lipids in Health and Disease          (2020) 19:214 Page 8 of 12
our understanding to grow. However, there is still pro-
gress to be made especially with respect to the role lipids
play in its regulation. For example, mass spectroscopy
techniques have significantly improved in recent years
allowing for the high throughput analysis and identifica-
tion of lipids present in a system. Other advances that
would facilitate new research could include an improved
way of visualizing and even purifying autophagosomes
and lysosomes. Current methods utilize immunoprecipi-
tation or density gradient fractionation, both of which
are known to result in significant levels of impurities, to
isolate these subcellular structures. In conclusion, lipids
play an important and diverse signaling role in autoph-
agy regulation, and it is necessary to fully characterize
lipid signal transduction pathways to better inform
autophagy-based therapies.
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